News

Category
  • All
  • Information
Information
2019.08.09

A Collaboration Research Related to Development of Mitochondrial Disease Treatment by 5-Aminolevulinic Acid and Sodium Ferrous Citrate was Published

SBI Pharmaceuticals Co., Ltd. Saitama Medical University Chiba Children’s Hospital Juntendo University SBI Pharmaceuticals Co., Ltd., (Head office: Minato-ku, Tokyo; Representative Director, President: Yoshitaka Kitao), a subsidiary of SBI Holdings, Inc., Saitama Medical University, Chiba Children’s Hospital and Juntendo University published a result from a collaboration study on Scientific Reports, of Nature Publishing Group. Mitochondrial […]
See more
Information
2019.06.18

The collaboration study with Cancer Chemotherapy Center of JFCR was published in Scientific Reports, an online journal of Nature

SBI Pharmaceuticals Co., Ltd., (Head office: Minato-ku, Tokyo; Representative Director, President: Yoshitaka Kitao), a subsidiary of SBI Holdings, Inc., and Division of Molecular Pharmacology, Cancer Chemotherapy Center, Japan Foundation for Cancer Research (Laboratory: Tokyo; Division Head: Shingo Dan) announce that the outcome from the mutual collaboration study was just published in Scientific Reports, an online journal of Nature.
See more

Category
  • All
  • News
News
2018.03.30

Comprehensive Commercialization Rights Granted to Neopharma on the Pharmaceuticals Containing 5-ALA

SBI Pharmaceuticals Co., Ltd., (Head office: Minato-ku, Tokyo; Representative Director & President: Yoshitaka Kitao; “SBI Pharmaceuticals”), a subsidiary of SBI Holdings, Inc., engaged in research and development of pharmaceuticals, health foods and cosmetics using 5-aminolevulinic acid (“5-ALA”)*1, hereby announces that SBI Pharmaceuticals has granted the comprehensive commercialization rights on the pharmaceuticals containing 5-ALA including “ALAGLIO Divided Granules 1.5g” in the territory of MENA *2 and India to neopharma Japan Co., Ltd. (Head office: Chiyoda-ku, Tokyo; Representative Director: Satofumi Kawata; “neopharma Japan”), a subsidiary of neopharma LLC *3, a company of the United Arab Emirates (UAE) engaged in production and marketing of pharmaceuticals.
See more
News
2018.01.25

Presentation of Research Paper on 5-ALA by Yamagata University, Faculty of Medicine to PLOS ONE, a U.S. Scientific Journal ~ 5-ALA Deficiency Attenuates Mitochondrial Function and Impairs Glucose Tolerance~

SBI Pharmaceuticals Co., Ltd. Yamagata University, Faculty of Medicine SBI Pharmaceuticals Co., Ltd., (Head office: Minato-ku, Tokyo; Representative Director & President: Yoshitaka Kitao), a subsidiary of SBI Holdings, Inc., engaged in the research and development of pharmaceuticals, health foods and cosmetics using 5-ALA (5-Aminolevulinic acid) (*1) and Yamagata University, Faculty of Medicine (Campus: Yamagata-shi, Yamagata; […]
See more

Category
  • All
  • Information
  • News
News
2017.12.18

Launch of the Photodynamic Diagnostic Agent “ALAGLIO® Divided Granules 1.5g” -Contributing to the Initial Treatment of Non-Muscle Invasive Bladder Cancer through the Visualization of Tumor Lesions –

Chugai Pharmaceutical Co., Ltd. SBI Pharmaceuticals Co., Ltd. TOKYO, December 18, 2017 — Chugai Pharmaceutical Co., Ltd. (Head office: Tokyo; Chairman & CEO: Osamu Nagayama; “Chugai”) announced that it will launch the photodynamic diagnostic agent, “ALAGLIO® Divided Granules 1.5g” (“this Agent”) on December 19th. This Agent was developed by SBI Pharmaceuticals Co., Ltd., (Head office: […]
See more
News
2017.09.27

“ALAGLIO® Divided Granules 1.5g,” a Photodynamic Diagnostic Agent Obtained Manufacture and Marketing Approval

SBI Pharmaceuticals Co., Ltd., (Head office: Minato-ku, Tokyo; Representative Director & President: Yoshitaka Kitao; “SBI Pharma”), a subsidiary of SBI Holdings, Inc., engaged in the research and development of medicines using 5-ALA (5-Aminolevulinic acid) (*1) and Chugai Pharmaceutical Co., Ltd. (Head office: Chuo-ku, Tokyo; Chairman & CEO: Osamu Nagayama; “Chugai”) hereby announce that the manufacture and marketing approval of a photodynamic diagnostic agent, “ALAGLIO® Divided Granules 1.5g” (Generic name: Aminolevulinic acid hydrochloride; “this Agent”) has been obtained from the Ministry of Health, Labour and Welfare for the indication of diagnostic agent to visualize non-muscle invasive bladder cancer at the operation of its transurethral resection.
See more
Information
2017.04.24

Positive Data of Phase III Clinical Trial in Patients of Non-Muscle Invasive Bladder Cancer were Presented at the 105th Annual Meeting of the Japanese Urological Association

SBI Pharmaceuticals Co., Ltd. SBI Pharmaceuticals Co., Ltd., (Head office: Minato-ku, Tokyo; Representative Director & President: Yoshitaka Kitao; “SBI Pharmaceuticals”), a subsidiary of SBI Holdings, Inc., engaged in research and development of pharmaceuticals, health foods and cosmetics using 5-aminolevulinic acid (“5-ALA”)(*1), hereby announces that the resection of bladder cancer by using aminolevulinic acid hydrochloride (SPP-005) […]
See more
News
2017.03.13

SBI Pharma and Chugai Enter an Agreement of Exclusive Marketing Rights for “ALAGLIO® Granule 1.5g” in Japan

SBI Pharmaceuticals Co., Ltd. Chugai Pharmaceutical Co., Ltd. TOKYO, March 13, 2017 — SBI Pharmaceuticals Co., Ltd. (Head Office: Minato-ku, Tokyo; Representative Director and President: Yoshitaka Kitao; “SBI Pharma”), a subsidiary of SBI Holdings, Inc., engaged in the research and development of medicines using 5-ALA* (5-Aminolevulinic acid), has entered a licensing agreement with Chugai Pharmaceutical […]
See more
News
2017.01.27

Notice on the Start of Phase II Clinical Trial using 5-ALA by University of Oxford and SBI Pharmaceuticals

SBI Holdings, Inc. SBI Pharmaceuticals Co., Ltd. University of Oxford SBI Pharmaceuticals Co., Ltd., (Head office: Minato-ku, Tokyo; Representative Director & President: Yoshitaka Kitao; “SBI Pharmaceuticals”), a subsidiary of SBI Holdings, Inc., engaged in research and development of pharmaceuticals, health foods and cosmetics using 5-aminolevulinic acid (“5-ALA”)*1 and the University of Oxford in the United […]
See more

Category
  • All
  • Information
  • News
News
2016.10.26

Exclusive License Agreement Concluded with Neopharma on the Therapeutic Drug s for Diabetes and Malaria Infection

SBI Pharmaceuticals Co., Ltd SBI Pharmaceuticals Co., Ltd., (Head office: Minato-ku, Tokyo; Representative Director & President: Yoshitaka Kitao; “SBI Pharmaceuticals”), a subsidiary of SBI Holdings, Inc., engaged in research and development of pharmaceuticals, health foods and cosmetics using 5-aminolevulinic acid (“5-ALA”)*1, hereby announces that SBI Pharmaceuticals has concluded the exclusive license agreement with Neopharma LLC. […]
See more
Information
2016.09.26

Research Paper on the Safety and Usefulness of 5-ALA in the Patients with Type 2 Diabetes in Bahrain in the Food Intervention Test Published in the “Journal of Diabetes Research”

SBI Holdings, Inc. SBI Pharmaceuticals Co., Ltd. SBI Pharmaceuticals Co., Ltd., (Head office: Minato-ku, Tokyo; Representative Director & President: Yoshitaka Kitao; “SBI Pharmaceuticals”), a subsidiary of SBI Holdings, Inc., engaged in research and development of pharmaceuticals, health foods and cosmetics using 5-aminolevulinic acid (“5-ALA”)*1, hereby announces that the research paper on the safety and usefulness […]
See more
Information
2016.07.20

Registration of a U. S. Patent for Treatment of Influenza Virus Infection through Joint Application with Tokushima University

SBI Pharmaceuticals Co., Ltd., (Head office: Minato-ku, Tokyo; President: Yoshitaka Kitao; “SBI Pharmaceuticals”), a subsidiary of SBI Holdings, Inc., engaged in research and development of pharmaceuticals, health foods and cosmetics using 5-aminolevulinic acid (“5-ALA”), hereby announces that a patent has recently been registered in the United States of America for the treatment of influenza virus infection.
See more
Information
2016.07.20

Registration of a U. S. Patent on the External Preparation for Skin Containing 5-ALA

SBI Pharmaceuticals Co., Ltd. SBI Pharmaceuticals Co., Ltd., (Head office: Minato-ku, Tokyo; President: Yoshitaka Kitao; “SBI Pharmaceuticals”), a subsidiary of SBI Holdings, Inc., engaged in research and development of pharmaceuticals, health foods and cosmetics using 5-aminolevulinic acid (“5-ALA”)*, hereby announces that a patent has recently been registered in the United States of America on the […]
See more
Information
2016.05.20

Registration of a Patent for Enhancer of Survival of Transplanted Organ through Joint Application with National Center for Child Health and Development

SBI Pharmaceuticals Co., Ltd. SBI Pharmaceuticals Co., Ltd., (Head office: Minato-ku, Tokyo; Representative Director and CEO: Yoshitaka Kitao; “SBI Pharmaceuticals”), a subsidiary of SBI Holdings, Inc., engaged in research and development of pharmaceuticals, health foods and cosmetics using 5-aminolevulinic acid (“5-ALA”)*, hereby announces that a patent has recently been registered in Japan for an agent […]
See more
Information
2016.05.20

Registration of a Patent for Treatment and Prevention of Radiation Damage through Joint Application with The University of Tokyo

SBI Pharmaceuticals Co., Ltd. SBI Pharmaceuticals Co., Ltd., (Head office: Minato-ku, Tokyo; Representative Director and CEO: Yoshitaka Kitao; “SBI Pharmaceuticals”), a subsidiary of SBI Holdings, Inc., engaged in research and development of pharmaceuticals, health foods and cosmetics using 5-aminolevulinic acid (“5-ALA”) (*1), hereby announces that a patent has recently been registered in Japan for the […]
See more
Information
2016.05.18

Registration of a Patent for Treatment and Prevention of Influenza Virus Infection through Joint Application with Tokushima University

SBI Pharmaceuticals Co., Ltd. SBI Pharmaceuticals Co., Ltd., (Head office: Minato-ku, Tokyo; Representative Director and CEO: Yoshitaka Kitao; “SBI Pharmaceuticals”), a subsidiary of SBI Holdings, Inc., engaged in research and development of pharmaceuticals, health foods and cosmetics using 5-aminolevulinic acid (“5-ALA”) (*1), hereby announces that a patent has recently been registered in Japan for the […]
See more
Information
2016.03.16

Registration of a Patent on a Device to Identify Cancer Metastasis in Sentinel Lymph Node

SBI Pharmaceuticals Co., Ltd. SBI Pharmaceuticals Co., Ltd., (Head office: Minato-ku, Tokyo; Representative Director and CEO: Yoshitaka Kitao; “SBI Pharmaceuticals”) is a subsidiary of SBI Holdings, Inc. that engaged in research and development of pharmaceuticals, health foods and cosmetics using 5-aminolevulinic acid (“5-ALA”) *1, hereby announces that a patent has recently been registered in Japan […]
See more
Information
2016.03.15

Registration of a Patent for Photodynamic Therapy Using a Photosensitizer or 5-Aminolevulinic Acids

SBI Pharmaceuticals Co., Ltd. SBI Pharmaceuticals Co., Ltd., (Head office: Minato-ku, Tokyo; Representative Director and CEO: Yoshitaka Kitao; “SBI Pharmaceuticals”), a subsidiary of SBI Holdings, Inc., engaged in research and development of pharmaceuticals, health foods and cosmetics using 5-aminolevulinic acid (5-ALA)*, hereby announces that a patent has recently been registered in Japan for a photodynamic […]
See more
Information
2016.03.14

Registration of a Patent for Treatment and Prevention of Cancer Anemia

SBI Pharmaceuticals Co., Ltd. SBI Pharmaceuticals Co., Ltd. (Head office: Minato-ku, Tokyo; Representative Director and CEO: Yoshitaka Kitao; “SBI Pharmaceuticals”), a subsidiary of SBI Holdings, Inc., engaged in research and development of pharmaceuticals, health foods and cosmetics using 5-aminolevulinic acid (“5-ALA”)*, hereby announces that a patent has recently been registered in Japan for the treatment […]
See more
Information
2016.03.14

Registration of a Patent for Treatment and Prevention of Chronic Kidney Disease

SBI Pharmaceuticals Co., Ltd. SBI Pharmaceuticals Co., Ltd., (Head office: Minato-ku, Tokyo; Representative Director and CEO: Yoshitaka Kitao; “SBI Pharmaceuticals), a subsidiary of SBI Holdings, Inc., engaged in research and development of pharmaceuticals, health foods and cosmetics using 5-aminolevulinic acid (“5-ALA”)*1, hereby announces that a patent has recently been registered in Japan for the treatment […]
See more
Information
2016.03.14

Registration of a Patent for Photodynamic Diagnosis and Photobleaching-Prevention Agent through Joint Application with Tokyo Institute of Technology

SBI Pharmaceuticals Co., Ltd. SBI Pharmaceuticals Co., Ltd., (Head office: Minato-ku, Tokyo; Representative Director and CEO: Yoshitaka Kitao; “SBI Pharmaceuticals”), a subsidiary of SBI Holdings, Inc., engaged in research and development of pharmaceuticals, health foods and cosmetics using 5-aminolevulinic acid (“5-ALA”)*1, hereby announces that a patent has recently been registered in Japan for a photodynamic […]
See more

Category
  • All
  • Information
  • News
Information
2015.10.22

Curative and Protective Effects of the Combined Treatment of 5-aminolevulinic Acid and Iron against Malaria Infection was Confirmed in Animal Model.

SBI Holdings, Inc. SBI Pharmaceuticals Co., Ltd. SBI Pharmaceuticals Co., Ltd. (Head office: Minato-ku, Tokyo; Representative Director and CEO: Yoshitaka Kitao; “SBI Pharmaceuticals”), a subsidiary of SBI Holdings, Inc., engages in research and development of pharmaceuticals, health foods and cosmetics using 5-aminolevulinic acid (“5-ALA”) (*1) announced in Antimicrobial Agents and Chemotherapy published on October 21 […]
See more
Information
2015.10.22

Registration of a U. S. Patent on a Method for Treating Diabetes Containing 5-ALA as an Active Ingredient

SBI Holdings, Inc. SBI Pharmaceuticals Co., Ltd. SBI Pharmaceuticals Co., Ltd. (Head office: Minato-ku, Tokyo; Representative Director and CEO: Yoshitaka Kitao; “SBI Pharmaceuticals”), a subsidiary of SBI Holdings, Inc., engages in research and development of pharmaceuticals, health foods and cosmetics using 5-aminolevulinic acid (“5-ALA”)*1. We are pleased to inform you that a U. S. Patent […]
See more
Information
2015.09.04

Product Registration of Food Supplement in Jordan

SBI Holdings, Inc. SBI Pharmaceuticals Co., Ltd. SBI Pharmaceuticals Co., Ltd. (Head office: Minato-ku, Tokyo; Representative Director and CEO: Yoshitaka Kitao; “SBI Pharmaceuticals”), a subsidiary of SBI Holdings, Inc., engages in research and development of pharmaceuticals, health foods and cosmetics using 5-aminolevulinic acid (“5-ALA”)*. We are pleased to inform that SBI Pharmaceuticals has received from […]
See more
Information
2015.06.08

ReproCELL and SBI Pharmaceuticals Develop Selective Removal Technology of Residual iPS Cells from iPS Derived-differentiated Cells for Regenerative Medicine Through Technological Application of SBI Pharmaceuticals’ 5-ALA

SBI Holdings, Inc. SBI Pharmaceuticals Co., Ltd. ReproCELL Inc. SBI Pharmaceuticals Co., Ltd. (Head office: Minato-ku, Tokyo; Representative Director and CEO: Yoshitaka Kitao; “SBI Pharmaceuticals”), a subsidiary of SBI Holdings, Inc. engaging in research and development of pharmaceuticals, health foods and cosmetics using 5-aminolevulinic acid (“5-ALA”)* and ReproCELL Inc. (Head office: Kohoku-ku, Yokohama, Kanagawa; Chief […]
See more
Information
2015.05.07

Acquisition of a Patent through Joint Application with National Hospital Organization for Therapeutic Agent for Allergic Rhinitis Containing 5-ALA as an Active Ingredient

SBI Holdings, Inc. SBI Pharmaceuticals Co., Ltd. SBI Pharmaceuticals Co., Ltd. (Head office: Minato-ku, Tokyo; Representative Director and CEO: Yoshitaka Kitao; “SBI Pharmaceuticals”), a subsidiary of SBI Holdings, Inc., engages in research and development of pharmaceuticals, health foods and cosmetics using 5-aminolevulinic acid (“5-ALA”)*. We are pleased to inform you that SBI Pharmaceuticals has obtained […]
See more
Information
2015.02.05

Release of Medical Light Source “Violet LD Light Source Alcedo LS-VSD”

SBI Holdings, Inc. SBI Pharmaceuticals Co., Ltd. SBI Pharmaceuticals Co., Ltd. (Head office: Minato-ku, Tokyo; Representative Director and CEO: Yoshitaka Kitao; “SBI Pharmaceuticals”), a subsidiary of SBI Holdings, Inc., engages in research and development of pharmaceuticals, health foods and cosmetics using 5-aminolevulinic acid (“5-ALA”)*. We are pleased to announce the launch of our new product, […]
See more
Information
2015.01.19

Acquisition of a Patent through Joint Application with Tokyo Institute of Technology

SBI Holdings, Inc. SBI Pharmaceuticals Co., Ltd. SBI Pharmaceuticals Co., Ltd. (Head office: Minato-ku, Tokyo; Representative Director and CEO: Yoshitaka Kitao; “SBI Pharmaceuticals”), a subsidiary of SBI Holdings, Inc., engages in research and development of pharmaceuticals, health foods and cosmetics using 5-aminolevulinic acid (“5-ALA”)*. We are pleased to inform you that we at SBI Pharmaceuticals […]
See more
Information
2015.01.16

Conclusion of a Patent Licensing Agreement with Cosmo Oil

SBI Holdings, Inc. SBI Pharmaceuticals Co., Ltd. SBI Pharmaceuticals Co., Ltd. (Head office: Minato-ku, Tokyo; Representative Director and CEO: Yoshitaka Kitao; “SBI Pharmaceuticals”), a subsidiary of SBI Holdings, Inc., engages in research and development of pharmaceuticals, health foods, cosmetics and medical devices for diagnosis using 5-aminolevulinic acid (“5-ALA”)*. We are pleased to inform you that […]
See more
Information
2015.01.14

Acquisition of a Patent for Prophylactic/Ameliorating Agent for Adult Diseases Containing 5-ALA as an Active Ingredient

SBI Holdings, Inc. SBI Pharmaceuticals Co., Ltd. SBI Pharmaceuticals Co., Ltd. (Head office: Minato-ku, Tokyo; Representative Director and CEO: Yoshitaka Kitao; “SBI Pharmaceuticals”), a subsidiary of SBI Holdings, Inc., engages in research and development of pharmaceuticals, health foods and cosmetics using 5-aminolevulinic acid (“5-ALA”)*1. We are pleased to inform you that SBI Pharmaceuticals has obtained […]
See more
Information
2014.08.21

Presentation of Research Paper on 5-ALA by Osaka City University to PLOS ONE, a U.S. Scientific Journal — Findings of ALA-PDT in killing MRSA, one of the major bacterial species causing in-hospital infections —

SBI Holdings, Inc. SBI Pharmaceuticals Co., Ltd. Osaka City University SBI  Pharmaceuticals  Co.,  Ltd.  (Head  office:  Minato-ku,  Tokyo;  Representative  Director  and  CEO:Yoshitaka Kitao; “SBI Pharmaceuticals”), a subsidiary of SBI Holdings, Inc. (Head office: Minato-ku, Tokyo; Representative Director and CEO: Yoshitaka Kitao) engaging in research and development of pharmaceuticals, health foods and cosmetics using 5-aminolevulinic acid […]
See more
Information
2014.07.30

Conclusion of Agreement on Joint Research between the University of Oxford in the United Kingdom and SBI Pharmaceuticals — Planning to start a phase II clinical trial to assess the effectiveness of 5-ALA in preventing a reduction in cardiac output after heart bypass surgery —

SBI Holdings, Inc. SBI Pharmaceuticals Co., Ltd. Oxford University SBI Pharmaceuticals and the University of Oxford in the United Kingdom have signed an agreement for joint research to start a phase II clinical trial to assess the effectiveness of 5-aminolevulinic acid (“5-ALA”) (*1) in preventing a reduction in cardiac output (*2) after heart bypass surgery. […]
See more
Information
2014.05.29

Proposal on Development of Green Light Source is Selected for NEDO’s “FY2013 Innovation Commercialization Venture Support Project”

SBI Holdings, Inc. SBI Pharmaceuticals Co., Ltd. SBI Pharmaceuticals Co., Ltd. (Head office: Minato-ku, Tokyo; Representative Director and CEO: Yoshitaka Kitao; “SBI Pharmaceuticals”) is a subsidiary of SBI Holdings, Inc. (Head office: Minato-ku, Tokyo; Representative Director and CEO: Yoshitaka Kitao; “SBIH”) engaging in research and development of pharmaceuticals, health foods and cosmetics using 5-aminolevulinic acid […]
See more
Information
2014.04.22

SBI Pharmaceuticals Officers to Serve as Visiting Professors at Fudan University in China

SBI Holdings, Inc. SBI Pharmaceuticals Co., Ltd. SBI Pharmaceuticals Co., Ltd. (Head office: Minato-ku, Tokyo; Representative Director and CEO: Yoshitaka Kitao; “SBI Pharmaceuticals”) is a subsidiary of SBI Holdings, Inc. (Head office: Minato-ku, Tokyo; Representative Director and CEO: Yoshitaka Kitao; “SBIH”) engaging in research and development of pharmaceuticals, health foods and cosmetics using 5-aminolevulinic acid […]
See more
News
2014.04.01

Release of Medical Light Source “Bicolor LED Light Source Aladuck LS-DLED”

SBI Holdings, Inc. SBI Pharmaceuticals Co., Ltd. SBI Pharmaceuticals Co., Ltd. (Head office: Minato-ku, Tokyo; Representative Director and CEO: Yoshitaka Kitao; “SBI Pharmaceuticals”), a subsidiary of SBI Holdings, Inc. (SBIH), engages in research and development of pharmaceuticals, health foods and cosmetics using 5-aminolevulinic acid (“5-ALA”)*1. SBI Pharmaceuticals will begin selling the bicolor medical LED light […]
See more
Information
2014.03.28

Notice Regarding Start of Clinical Studies on Type 2 Diabetes by Using 5-ALA at the Bahrain Defense Force Royal Medical Service Hospital

SBI Holdings, Inc. SBI Pharmaceuticals Co., Ltd. SBI Pharmaceuticals Co., Ltd. (Head office: Minato-ku, Tokyo; Representative Director and CEO: Yoshitaka Kitao; “SBI Pharmaceuticals”) is a subsidiary of SBI Holdings, Inc. engaged in research and development of pharmaceuticals, health foods and cosmetics using 5-aminolevulinic acid (5-ALA) (*1). It has been engaging in the 5-aminolevulinic acid (“5-ALA”) […]
See more
News
2014.03.17

ReproCELL and SBI Pharmaceuticals Agree on a Joint Research Regarding ES/iPS Cell Technology Using 5-ALA

SBI Holdings, Inc. SBI Pharmaceuticals Co., Ltd. ReproCELL Inc. SBI Pharmaceuticals Co., Ltd. (Head office: Minato-ku, Tokyo; Representative Director and CEO: Yoshitaka Kitao; “SBI Pharmaceuticals”), a subsidiary of SBI Holdings, Inc. engaging in research and development of pharmaceuticals, health foods and cosmetics using 5-aminolevulinic acid (“5-ALA”)*1 and ReproCELL Inc. (Head office: Kohoku-ku, Yokohama, Kanagawa; Chief […]
See more
Information
2014.02.03

Announcement of Communication to Grant a Patent in Europe for Therapeutic Agent for Male Sterility through Administration of 5-Aminolevulinic Acid

SBI Holdings, Inc. SBI Pharmaceuticals Co., Ltd. SBI Pharmaceuticals Co., Ltd. (Head office: Minato-ku, Tokyo; Representative Director and CEO: Yoshitaka Kitao; “SBI Pharmaceuticals”), a subsidiary of SBI Holdings, Inc. (SBIH), engages in research and development of pharmaceuticals, health foods and cosmetics using 5-aminolevulinic acid (“5-ALA”)*1. We are pleased to announce that the European Patent Office […]
See more
Information
2014.01.21

Announcement of Decision to Grant a Patent in Japan for Method of Detecting Bladder Cancer through Oral Administration of 5-Aminolevulinic Acid

SBI Holdings, Inc. SBI Pharmaceuticals Co., Ltd. SBI Pharmaceuticals Co., Ltd. (Head office: Minato-ku, Tokyo; Representative Director and CEO: Yoshitaka Kitao; “SBI Pharmaceuticals”), a subsidiary of SBI Holdings, Inc. (SBIH), engages in research and development of pharmaceuticals, health foods and cosmetics using 5-aminolevulinic acid (“5-ALA”)*1. We are pleased to announce that we have been received […]
See more
Information
2014.01.16

Announcement of the First Successful Surgical Removal of Bladder Cancer in the Middle East Using 5-Aminolevulinic Acid as an Intraoperative Diagnostic Drug at a Medical Center of Arabian Gulf University in Bahrain

SBI Holdings, Inc. SBI Pharmaceuticals Co., Ltd. The SBI Group is engaged in research and development of pharmaceuticals, health foods and cosmetics using 5-aminolevulinic acid (“5-ALA”) at SBI Pharmaceuticals Co., Ltd. (Head office: Minato-ku, Tokyo; Representative Director and CEO: Yoshitaka Kitao; “SBI Pharmaceuticals”), a subsidiary of SBI Holdings, Inc. We are pleased to inform you […]
See more
Information
2013.12.18

Presentation of Research Paper on 5-ALA by Kochi University to PLoS ONE, a U.S. Scientific Journal — Findings of 5-Aminolevulinic Acid (5-ALA) in Protecting against Cisplatin-Induced Acute Kidney Injury (AKI) —

SBI Holdings, Inc. SBI Pharmaceuticals Co., Ltd. The SBI Group is engaged in research and development of pharmaceuticals, health foods and cosmetics using 5-aminolevulinic acid (“5-ALA”) at SBI Pharmaceuticals Co., Ltd. (Head office: Minato-ku, Tokyo; Representative Director and CEO: Yoshitaka Kitao; “SBI Pharmaceuticals”), a subsidiary of SBI Holdings, Inc. (SBIH). We are pleased to inform […]
See more
Information
2013.12.03

Findings of Mechanism of 5-aminolevulinic Acid (5-ALA) and Iron in Synergistically Inhibiting Growth of Plasmodium Falciparum Malaria Parasites

The University of Tokyo Tokyo Institute of Technology MRC National Institute for Medical Research SBI Pharmaceuticals Co., Ltd. The University of Tokyo, a national university (main campus: Bunkyo-ku, Tokyo; President: Junichi Hamada), Tokyo Institute of Technology, a national university (main campus: Meguro-ku, Tokyo; President: Yoshinao Mishima),MRC National Institute for Medical Research (London, U.K. Director: Jim […]
See more
News
2013.09.26

New Launch of “ALAGLIO® Internal Medicine 1.5g,” an Orally-administered in vivo Diagnostic Agent for Malignant Glioma

SBI Holdings, Inc. SBI Pharmaceuticals Co., Ltd. We  are  pleased   to  inform  you  that  SBI  Pharmaceuticals   Co.,  Ltd.  (Head  office:  Minato-ku,   Tokyo; Representative Director and CEO: Yoshitaka Kitao; “SBI Pharmaceuticals”), a subsidiary of SBI Holdings, Inc., engaged in research and development of pharmaceuticals, health foods and cosmetics using 5-aminolevulinic acid (5-ALA) (*), announces that today […]
See more
News
2013.09.20

SBI Pharmaceuticals Obtains a Business License for Selling and Renting Highly Controlled Medical Devices

SBI Holdings, Inc. SBI Pharmaceuticals Co., Ltd. We  are  pleased   to  inform  you  that  SBI  Pharmaceuticals   Co.,  Ltd.  (Head   office:  Minato-ku,   Tokyo; Representative Director and CEO: Yoshitaka Kitao; “SBI Pharmaceuticals”), a subsidiary of SBI Holdings, Inc., engaged in research and development of pharmaceuticals, health foods and cosmetics using 5-aminolevulinic acid (5-ALA) (*), announces that it […]
See more
Information
2013.08.30

SBI Pharmaceuticals Submits a Phase-2 Clinical Trial CTA to MHRA for a Drug to Treat Cancer Chemotherapy-induced Anemia

SBI Holdings, Inc. (TOKYO: 8473 / Hong Kong: 6488) SBI Pharmaceuticals Co., Ltd., (Head office: Minato-ku, Tokyo; Representative Director and CEO: Yoshitaka Kitao; hereinafter “SBI Pharmaceuticals”), a subsidiary of SBI Holdings, Inc., which researches and develops pharmaceuticals, health foods, and cosmetics using 5-aminolevulinic acid (5-ALA) (*1) has submitted a clinical trial application (CTA) to the […]
See more
News
2013.08.27

Announcement—the new drug “ALAGLIO® Internal Medicine 1.5g”, an Orally-administered in vivo Diagnostic for Malignant Glioma, is Listed on the NHI Drug Price List

SBI Holdings, Inc. SBI Pharmaceuticals Co., Ltd. We are pleased to inform you that SBI Pharmaceuticals Co., Ltd. (Head office: Minato-ku, Tokyo; Representative Director and CEO: Yoshitaka Kitao; “SBI Pharmaceuticals”), a subsidiary of SBI Holdings, Inc., engaged in research and development of pharmaceuticals, health foods and cosmetics using 5-aminolevulinicacid (5-ALA) (*), announces that the in […]
See more
News
2013.08.26

Notice Regarding Conclusion of Basic Agreement with King Hamad University Hospital in Bahrain on Clinical Study of 5 a minolevulinic a cid

SBI Holdings, Inc. SBI Pharmaceuticals Co., Ltd. We are pleased to inform you that SBI Pharmaceuticals Co., Ltd. (Head office: Minato-ku, Tokyo; Representative Director and CEO: Yoshitaka Kitao; “SBI Pharmaceuticals”), a subsidiary of SBI Holdings, Inc., engaged in research and development of pharmaceuticals, health foods and cosmetics using 5-aminolevulinic acid (5-ALA) (*), has entered into […]
See more
News
2013.03.25

SBI Pharmaceuticals Obtains Manufacture and Marketing Approval for Orally-administered in vivo Diagnostic Agent “ALAGLIO®” for Malignant Glioma — Japan’s First Orally-administered Fluorescence Diagnostic Agent for Use in the Surgical Resection of Brain Tumor

SBI Holdings, Inc. SBI Pharmaceuticals Co., Ltd. We are pleased to inform you that SBI Pharmaceuticals Co., Ltd. (Head office: Minato-ku, Tokyo; Representative Director and CEO: Yoshitaka Kitao; “SBI Pharmaceuticals”), a subsidiary of SBI Holdings, Inc., which is engaged in research and development of pharmaceuticals, health foods and cosmetics using 5-aminolevulinic acid (“5-ALA”), has obtained […]
See more
News
2013.03.21

Joint Clinical Research on Diabetes with Arabian Gulf University in Bahrain

SBI Holdings, Inc. SBI Pharmaceuticals Co., Ltd. We are pleased to inform you that SBI Pharmaceuticals Co., Ltd. (Head office: Minato-ku, Tokyo; Representative Director and CEO: Yoshitaka Kitao; “SBI Pharmaceuticals”), a subsidiary of SBI Holdings, Inc., which is engaged in research and development of pharmaceuticals, health foods and cosmetics using 5-aminolevulinic acid (5-ALA) (*1) has […]
See more
Information
2013.03.21

Basic Agreement Reached with the Bahrain Development Bank for Promoting 5-ALA Business in Bahrain

SBI Holdings, Inc. SBI Pharmaceuticals Co., Ltd. We are pleased to inform you that SBI Pharmaceuticals Co., Ltd. (Head office: Minato-ku, Tokyo; Representative Director and CEO: Yoshitaka Kitao; “SBI Pharmaceuticals”), a subsidiary of SBI Holdings, Inc., engaged in research and development of pharmaceuticals, health foods and cosmetics using 5-aminolevulinic acid (5-ALA) (*1), has reached a […]
See more
News
2013.03.21

Notice on the Establishment of Joint Venture Company with Dawani Group Holding, a Major Corporate Group in Bahrain

SBI Holdings, Inc. SBI Pharmaceuticals Co., Ltd. We are pleased to inform you that SBI Pharmaceuticals Co., Ltd. (Head office: Minato-ku, Tokyo; Representative Director and CEO: Yoshitaka Kitao; “SBI Pharmaceuticals”), a subsidiary of SBI Holdings, Inc., which is engaged in research and development of pharmaceuticals, health foods and cosmetics using 5-aminolevulinic acid (5-ALA) (*1) has […]
See more
News
2013.03.21

Memorandum of Understanding between Mumtalakat, the Sovereign Wealth Fund of Bahrain, and SBI Pharmaceuticals Co., Ltd. to Cooperate in the 5-ALA Business in Bahrain Focusing on the Pharmaceuticals Industry

SBI Holdings, Inc. SBI Pharmaceuticals Co., Ltd. We are pleased to inform you that SBI Pharmaceuticals Co., Ltd. (Head office: Minato-ku, Tokyo; Representative Director and CEO: Yoshitaka Kitao; “SBI Pharmaceuticals”), a subsidiary of SBI Holdings, Inc., has entered into a memorandum of understanding with Bahrain Mumtalakat Holding Company B.S.C. (c) (Head office: Manama, Bahrain; Chief […]
See more
News
2013.03.21

Agreement to Collaborate Reached with the Royal College of Surgeons in Ireland – Medical University of Bahrain for Starting Clinical Studies

SBI Holdings, Inc. SBI Pharmaceuticals Co., Ltd. We are pleased to inform you that SBI Pharmaceuticals Co., Ltd. (Head office: Minato-ku, Tokyo; Representative Director and CEO: Yoshitaka Kitao; “SBI Pharmaceuticals”), a subsidiary of SBI Holdings, Inc., engaged in research and development of pharmaceuticals, health foods and cosmetics using 5-aminolevulinic acid (5-ALA) (*1), has reached an […]
See more
News
2013.02.07

Notice on the Establishment of Joint Venture Company with Dawani Group Holding, Bahrain’s Major Corporate Group for Sales of 5-ALA Products

SBI Holdings, Inc. SBI Pharmaceuticals Co., Ltd. We are pleased to inform you that SBI Pharmaceuticals Co., Ltd. (Head office: Minato-ku, Tokyo; Representative Director and CEO: Yoshitaka Kitao; “SBI Pharmaceuticals”), a subsidiary of SBI Holdings, Inc., engaged in research and development of pharmaceuticals, health foods and cosmetics using 5-aminolevulinic acid (5-ALA) (*1) has reached a […]
See more
News
2013.01.21

SBI Pharmaceuticals Announces Conclusion of Basic Agreement to Start Clinical Research on Diabetes with Arabian Gulf University in Bahrain

SBI Pharmaceuticals Co., Ltd., (Head office: Minato-ku, Tokyo; Representative Director and CEO: Yoshitaka Kitao), a subsidiary of SBI Holdings, Inc., which researches and develops pharmaceuticals, health foods, and cosmetics using 5-aminolevulinic acid (5-ALA) (*1) announces that it has concluded a Basic Agreement to begin clinical research on diabetes in Bahrain with the Arabian Gulf University (AGU).
See more
Information
2013.01.16

Notice on the Press Release Published by the Bahrain Economic Development Board

SBI Pharmaceuticals Co., Ltd SBI Pharmaceuticals Co., Ltd. (Head office: Minato-ku, Tokyo; Representative Director and CEO: Yoshitaka Kitao), a subsidiary of SBI Holdings, Inc., engaged in research and development of pharmaceuticals, cosmetics and health foods using 5-aminolevulinic acid (5-ALA) officially acquired a permit of opening a representative office on October 9, 2012, as announced in […]
See more
Information
2013.01.07

SBI Pharmaceuticals Submits a Phase-1 Clinical Trial IND to U.S. FDA for a Drug to Treat Cancer Chemotherapy-induced Anemia

SBI Holdings, Inc. (TOKYO: 8473 / Hong Kong: 6488) SBI Pharmaceuticals Co., Ltd., (Head office: Minato-ku, Tokyo; Representative Director and CEO: Yoshitaka Kitao; “SBI Pharmaceuticals”), a subsidiary of SBI Holdings, Inc., which researches and develops pharmaceuticals, health foods, and cosmetics using 5-aminolevulinic acid (5-ALA) (*1) has submitted an Investigational New Drug Application (IND) to the […]
See more
Information
2012.10.30

SBI Pharmaceuticals Submits a Phase-1 Clinical Trial CTA to MHRA for a Drug to Treat Cancer Chemotherapy-induced Anemia

SBI Holdings, Inc. SBI Pharmaceuticals Co., Ltd SBI Pharmaceuticals Co., Ltd., (Head office: Minato-ku, Tokyo; Representative Director and CEO: Yoshitaka Kitao), a subsidiary of SBI Holdings, Inc., which researches and develops pharmaceuticals, health foods, and cosmetics using 5-aminolevulinic acid (5-ALA) (*1) has submitted a clinical trial application (CTA) to the Medicines and Healthcare products Regulatory […]
See more
Information
2012.10.11

SBI Pharmaceuticals Obtains the Product License of Healthy Supplement from the Dubai Authority

SBI Holdings, Inc. SBI Pharmaceuticals Co., Ltd. SBI Pharmaceuticals Co., Ltd., (Head office: Minato-ku, Tokyo; Representative Director and CEO: Yoshitaka Kitao), a subsidiary of SBI Holdings, Inc. that conducts research and development of pharmaceuticals, health foods and cosmetics using 5-aminolevulinic acid (5-ALA) (*1) announced that SBI Pharmaceuticals obtained the Product License of healthy supplement on […]
See more
Information
2012.10.10

SBI Pharmaceuticals Opens a Representative Office in Bahrain

SBI Pharmaceuticals Co., Ltd. SBI Pharmaceuticals Co., Ltd. (Head office: Minato-ku, Tokyo; Representative Director and CEO: Yoshitaka Kitao), a subsidiary of SBI Holdings, Inc., engaged in research and development of pharmaceuticals, cosmetics and health foods using 5-aminolevulinic acid (5-ALA), opens a representative office in Manama, the capital of Bahrain. As announced in the press release […]
See more
Information
2012.09.20

Notice on the Appointment of a New Executive Officer

SBI Pharmaceuticals Co., Ltd. SBI Pharmaceuticals Co., Ltd. (head office: Minato-ku, Tokyo; Representative Director and CEO: Yoshitaka Kitao; “SBI Pharmaceuticals”), a subsidiary of SBI Holdings, Inc., is engaged in research and development of cosmetics, health foods and drugs using 5-aminolevulinic acid (5-ALA). SBI Pharmaceuticals hereby announces that a new executive officer was appointed effective September […]
See more
News
2012.08.01

Notice on the Appointment of a New Director

SBI Pharmaceuticals Co., Ltd SBI Pharmaceuticals Co., Ltd. (head office: Minato-ku, Tokyo; Representative Director and CEO: Yoshitaka Kitao; “SBI Pharmaceuticals”), an affiliate company of SBI Holdings, Inc. , is engaged in research and development of cosmetics, health foods and drugs using 5-aminolevulinic acid (5-ALA). SBI Pharmaceuticals hereby announces that a new director was elected and […]
See more
Information
2012.07.06

Notice on application for marketing approval of in vivo diagnostic agent for malignant glioma in Japan

SBI Holdings, Inc. (TOKYO: 8473 / Hong Kong: 6488) SBI Pharmaceuticals Co., Ltd. SBI Pharmaceuticals Co., Ltd. (head office: Minato-ku, Tokyo; Representative Director and CEO: Yoshitaka Kitao; “SBI Pharmaceuticals”) ,affiliate company of SBI Holdings, Inc. ,is engaged in research and development of cosmetics, health foods and drugs using 5-aminolevulinic acid (5-ALA). SBI Pharmaceuticals and Nobelpharma […]
See more
Information
2012.06.26

Notice on Publication by Univ. of Hawaii of Paper on 5-ALA in Electronic Edition of U.S. Science Journal Clinical and Translational Science Publication of the results of clinical studies on the relationship between 5-ALA and glucose levels

SBI Holdings, Inc. SBI Pharmaceuticals Co., Ltd. SBI Holdings, Inc. (“SBIH”) conducts research and development on cosmetics, health foods and pharmaceuticals using 5-aminolevulinic acid (5-ALA) at its subsidiary SBI Pharmaceuticals Co., Ltd. (head office: Minato-ku, Tokyo; Representative: Yoshitaka Kitao; “SBI Pharmaceuticals”). In relation to this, The University of Hawaii at Manoa Group has recently published […]
See more
News
2012.04.24

SBI Pharmaceuticals Announces Obtainment of Marketing Authorization of Products Containing 5-ALA from The Kingdom of Bahrain Ministry of Health

Tokyo, April 24, 2012-SBI Pharmaceuticals Co., Ltd., announced that they had obtained Marketing Authorization of their products containing 5-ALA (*1) from The Kingdom of Bahrain Ministry of Health. SBI Pharmaceuticals signed a Memorandum of Understanding with the Government of The Kingdom of Bahrain for intensive collaboration of R&D and distribution of 5-ALA in Bahrain and […]
See more
Information
2012.04.13

Notice on Agreement with Bahrain Government for the Promotion of the 5-ALA Business

SBI Holdings, Inc. (TOKYO: 8473 / Hong Kong: 6488) It is hereby notified that SBI Pharmaceuticals Co., Ltd., the SBI Holdings, Inc. subsidiary engaged in the research and development of cosmetics, health foods and drugs using 5-aminolevulinic acid (5-ALA) (*1) (head office: Minato-ku, Tokyo; Representative Director and CEO: Yoshitaka Kitao; hereafter called “SBI Pharmaceuticals”) reached […]
See more
News
2012.02.29

Notice on SBI ALApromo’s Obtainment of First-class Marketing Authorization and Restructuring of ALA-related Business

SBI Holdings, Inc. (TOKYO: 8473 / Hong Kong: 6488) SBI ALApromo Co., Ltd., (head office: Minato-ku, Tokyo; Representative Director and CEO: Yoshitaka Kitao; “SBI ALApromo”), a subsidiary of SBI Holdings, Inc., that conducts research and development of cosmetics, health foods and pharmaceuticals using 5-aminolevulinic acid (ALA)*1, hereby announces that it has obtained First-class Marketing Authorization […]
See more
News
2011.10.28

ALA Study Results Presented at the 49th Annual Meeting of Japan Society of Clinical Oncology (1)
– Success in diagnosis of peritoneal dissemination using ALA –

SBI ALApromo Co., Ltd. SBI ALApromo Co., Ltd., (Head office: Minato-ku, Tokyo; Representative Director and CEO: Yoshitaka Kitao; “SBI ALApromo”), a subsidiary of SBI Holdings, Inc. that conducts research and development of cosmetics, health foods and pharmaceuticals using 5-aminolevulinic acid (ALA)*1, has succeeded in the detection of peritoneal dissemination of gastric cancer using ALA in […]
See more
Information
2011.10.28

ALA Study Results Presented at the 49th Annual Meeting of Japan Society of Clinical Oncology (2)
– Success in diagnosis of peritoneal dissemination and lymph node metastasis using ALA –

SBI ALApromo Co., Ltd. SBI ALApromo Co., Ltd., (Head office: Minato-ku, Tokyo; Representative Director and CEO: Yoshitaka Kitao; “SBI ALApromo”), a subsidiary of SBI Holdings, Inc. that conducts research and development of cosmetics, health foods and pharmaceuticals using 5-aminolevulinic acid (ALA)*1 has succeeded in the detection of peritoneal dissemination of gastric cancer and lymph node […]
See more
Information
2011.10.21

ALA Study Results Presented at Japanese Cancer Association, 70th Annual Meeting (2)
– Finding of ALA’s effect of enhancing hyperthermia therapy –

SBI ALApromo Co., Ltd. SBI ALApromo Co., Ltd. (Head Office: Minato-ku, Tokyo; Representative Director and CEO: Yoshitaka Kitao; “SBI ALApromo”), a subsidiary of SBI Holdings, Inc. which conducts research and development of cosmetics, health foods, and pharmaceuticals using 5-aminolevulinic acid (ALA)*1, has discovered that ALA has the effect of enhancing hyperthermia therapy, in joint research […]
See more
News
2011.10.21

ALA Study Results Presented at 39th Annual Meeting of Japanese Association for Acute Medicine
– Discovery of ALA’s inhibitory effect on inflammatory cytokine production –

SBI ALApromo Co., Ltd SBI ALApromo Co., Ltd. (Head Office: Minato-ku, Tokyo; Representative Director and CEO: Yoshitaka Kitao; “SBI ALApromo”), a subsidiary of SBI Holdings, Inc. that conducts research and development of cosmetics, health foods, and pharmaceuticals using 5-aminolevulinic acid (ALA)*1, has discovered in joint research with Nihon University that ALA has the effect of […]
See more
Information
2011.10.05

The study Results of ALA Presented Japanese Cancer Association, 70th Annual Meeting (1)
– Finding of ALA’s life-prolonging effect in mice with cancer –

SBI ALApromo Co., Ltd. SBI ALApromo Co., Ltd. (Head Office: Minato-ku, Tokyo; Representative Director and CEO: Yoshitaka Kitao; “SBI ALApromo”), a subsidiary of SBI Holdings, Inc. that conducts research and development of cosmetics, health foods, and pharmaceuticals using 5-aminolevulinic acid (ALA)*1 has discovered that administration of ALA had the effect of controlling debilitation of cancer-bearing […]
See more
Information
2011.10.05

ALA Study Results Presented at Japanese Cancer Association, 70th Annual Meeting (3)
– Identification of sensitivity determinant in photodynamic therapy using ALA –

SBI ALApromo Co., Ltd. SBI ALApromo Co., Ltd. (Head Office: Minato-ku, Tokyo; Representative Director and CEO: Yoshitaka Kitao; “SBI ALApromo”), a subsidiary of SBI Holdings, Inc. that conducts research and development of cosmetics, health foods, and pharmaceuticals using 5-aminolevulinic acid (ALA)*1 has identified a factor that determines sensitivity to photodynamic therapy using ALA, with Tokyo […]
See more
Information
2011.10.03

ALA Study Results Presented at Japanese Society of Parasitology, 71st Meeting.
– Findings of ALA’s growth inhibiting effect against P. falciparum malaria parasite growth –

SBI ALApromo Co., Ltd. SBI ALApromo Co., Ltd. (Head Office: Minato-ku, Tokyo; Representative Director and CEO: Yoshitaka Kitao; “SBI ALApromo”), a subsidiary of SBI Holdings, Inc. that conducts research and development of cosmetics, health foods, and pharmaceuticals using 5-aminolevulinic acid (ALA)*1, has found that ALA, a natural amino acid, has a growth inhibiting effect on […]
See more
News
2011.03.18

Announcement of publication of ALA research in International Immunopharmacology

SBI ALApromo Co., Ltd. SBI ALApromo Co., Ltd. (head office: Minato-ku, Tokyo; Representative Director and CEO: Yoshitaka Kitao; “SBI ALApromo”), a subsidiary of SBI Holdings, Inc., that conducts the research and development of cosmetics, health foods and medicines containing 5-aminolevulinic acid (ALA) is pleased to announce that its research paper on the diagnosis and treatment […]
See more
News
2010.11.30

Announcement of orphan drug designation granted to orally active IN VIVO diagnostic agent for malignant glioma

SBI Holdings, Inc. SBI ALApromo Co., Ltd. Nobelpharma Co., Ltd. SBI ALApromo Co., Ltd. (head office: Minato-ku, Tokyo; Representative Director and CEO: Yoshitaka Kitao; “SBI ALApromo”), a subsidiary of SBI Holdings, Inc., that conducts the research and development of cosmetics, health foods and medicines containing 5-aminolevulinic acid (ALA) *1 and Nobelpharma Co., Ltd. (head office: […]
See more
News
2010.05.27

Announcement of initiation of Phase III clinical study of orally active IN VIVO diagnostic agent for malignant glioma

SBI Holdings, Inc. SBI ALApromo Co., Ltd. Nobelpharma Co., Ltd. SBI ALApromo Co., Ltd. (head office: Minato-ku, Tokyo; Representative Director and CEO: Yoshitaka Kitao; “SBI ALApromo”), a subsidiary of SBI Holdings, Inc., that conducts the research and development of cosmetics, health foods and medicines containing 5-aminolevulinic acid (ALA)*1, has reached agreement in principle with Nobelpharma […]
See more
News
2010.04.01

Announcement of appointment of new executive officer

SBI Holdings, Inc. SBI ALApromo Co., Ltd. SBI ALApromo Co., Ltd. (head office: Minato-ku, Tokyo; Representative Director and CEO: Yoshitaka Kitao; “SBI ALApromo”), a subsidiary of SBI Holdings, Inc., that conducts the research and development of cosmetics, health foods and medicines containing 5-aminolevulinic acid (ALA)*1, is pleased to announce the appointment of Motowo Nakajima as […]
See more
News
2009.06.05

Joint Venture Formed with German Manufacturer medac to Pursue Pharmaceutical Development in Europe

SBI ALApromo Co., Ltd. (Head office: Minato-ku, Tokyo; “SBI ALApromo”), a subsidiary of SBI Holdings, Inc. that researches, develops and markets cosmetics, health foods, and medicines using 5-aminolevulinic acid (ALA), and medac GmbH (Head office: Wedel, Germany; “medac”), have signed an agreement on forming a joint venture company aimed at joint development of medicines in Europe.
See more
News
2008.05.27

Biotechnology Joint Venture Agreement Signed between SBI Holdings and Cosmo Oil

SBI Holdings, Inc. COSMO OIL Co., Ltd. SBI Holdings, Inc. (Head office: Roppongi, Minato-ku, Tokyo; Representative: Yoshitaka Kitao; “SBI Holdings”) and Cosmo Oil Co., Ltd. (Head office: Shibaura, Minato-ku, Tokyo; Representative: Yaichi Kimura; “Cosmo Oil”) have signed today a joint venture agreement for the purpose of jointly developing “5-aminolevulinic acid (5-ALA),” a type of amino […]
See more
News
2008.04.24

SBI ALApromo Co., Ltd. Founded to Pursue New Business in the Biotechnology

SBI Holdings, Inc. SBI Holdings, Inc. (“the Company”) has founded SBI ALApromo Co., Ltd. (“SBI ALApromo”), a preparatory company that develops and markets medicines, cosmetics, and health food containing amino acid “5-aminolevulinic acid” (5-ALA) as an active ingredient. “5-ALA” is a natural amino acid that might appear 3.6 billion years ago and some foods such […]
See more

Mechanical Translations by Google »